Skip to content

Phibro Animal Health PAHC Return on equity

Return on equity at other companies

Merck & Co. logo
Merck & Co.MRK
19%-20.3pp
Zoetis logo
ZoetisZTS
67%+15.8pp
Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
-3.8%-9.9pp
Neogen logo
NeogenNEOG
-25.6%+28.8pp
Balchem logo
BalchemBCPC
12.7%+0.7pp
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-335.8%-377pp

Other financials

Income statement

See full
Revenue$383.5M+10.3%
Gross profit$125.7M+20.2%
Operating income$44.7M+33.2%
Net income$24.0M+15.1%
EPS (diluted)$0.59+15.7%

Balance sheet

See full
Cash & equivalents$54.9M-9.0%
Total debt$32.3M+27.8%
Total equity$361.8M+36.0%
Total assets$1.4B+9.7%

Cash flow

See full
Operating cash flow$16.2M-62.4%
CapEx$15.3M+97.7%
Free cash flow$890.0K-97.5%

Valuation

See full
Market cap$1.27B+31.4%
Enterprise value$1.25B+33.9%
P/E13.4×-17.1×
P/S0.9×0.0×

Profitability

See full
Gross margin32.5%+0.9pp
Operating margin12%+4.0pp
Net margin6.3%+3.7pp
FCF margin0.9%-3.3pp

Returns & leverage

See full
Debt / equity0.1×0.0×
Current ratio3.2×+0.3×

Where this comes from

Calculated from Phibro Animal Health’s reported figures.

Based on trailing twelve months.

The official record: Phibro Animal Health’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phibro Animal Health's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phibro Animal Health's return on equity?
Phibro Animal Health (PAHC) reported return on equity of 30.3% in Q1 2026.
How has Phibro Animal Health's return on equity changed year-over-year?
Phibro Animal Health's return on equity increased by 155.8% year-over-year, from 11.9% to 30.3%.
What is the long-term trend for Phibro Animal Health's return on equity?
Over 4 years (2021 to 2025), Phibro Animal Health's return on equity has grown at a -8.6% compound annual growth rate (CAGR), from 25.5% to 17.8%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.